Pharmacokinetics, Tolerability, and Safety of Single and Multiple Omecamtiv Mecarbil Doses in Healthy Japanese and Caucasian Subjects

• Published in: European journal of drug metabolism and pharmacokinetics Vol. 46; no. 6; pp. 759 - 770
• Main Authors: Trivedi, Ashit, Malik, Fady I., Mackowski, Mia, Hutton, Shauna, Aoki, Makoto, Abbasi, Siddique, Dutta, Sandeep, Lee, Edward
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.11.2021
• Subjects: Administration, Oral; Adult; Area Under Curve; Asians; Biological Availability; Biomedical and Life Sciences; Biomedicine; Female; Half-Life; Healthy Volunteers; Human Physiology; Humans; Japan; Male; Medical Biochemistry; Original Research Article; Pharmaceutical Sciences/Technology; Pharmacology/Toxicology; Pharmacy; Tablets - adverse effects; Tablets - pharmacokinetics; Urea - adverse effects; Urea - analogs & derivatives; Urea - pharmacokinetics; Japan

Background and Objectives Omecamtiv mecarbil (OM) is a cardiac myosin activator under development for the treatment of heart failure. The pharmacokinetics of single and multiple doses of OM were investigated in healthy Japanese subjects in two clinical studies. Methods Study 1 ( n = 36) evaluated th...